On September 10, 2021 Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that management will present at the following investor conferences in September (Press release, Immunocore, SEP 10, 2021, View Source [SID1234590901]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 23rd Annual Global Investment Conference
Fireside Chat available on demand starting at 7:00 a.m. ET on Monday, September 13, 2021
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Fireside Chat: Wednesday, September 22, 2021 at 2:05 p.m. ET
The investor conferences will each be held in a virtual format and a live webcast of each presentation can be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. For conferences that offer replays, presentations will be made available for a limited time.